Prostate cancer trial combines four treatments to fight recurrence

NCT ID NCT04194554

Ongoing Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of a targeted drug (niraparib), hormone therapy, and precise radiation for men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach improves the chance of staying cancer-free for three years. About 100 men will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib (a PARP inhibitor), leuprolide (hormone blocker), abiraterone acetate (hormone blocker), and stereotactic body radiotherapy (focused radiation)
What this could lead to: If successful, this combination could offer a more effective treatment for high-risk prostate cancer, potentially delaying or preventing recurrence.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to all patients. The drug combination may cause serious side effects, and it's unclear if it will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Cornell University

New York, New York, 10065, United States
Mayo Clinic

Rochester, Minnesota, 55901, United States
University Hospitals Seidman Cancer Center

Cleveland, Ohio, 44106, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States
Weill Cornell Medicine

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.